Table of Contents Author Guidelines Submit a Manuscript
Multiple Sclerosis International
Volume 2011, Article ID 153282, 6 pages
http://dx.doi.org/10.1155/2011/153282
Research Article

CCR5Δ32 Polymorphism Associated with a Slower Rate Disease Progression in a Cohort of RR-MS Sicilian Patients

Department of Biomorphology and Biotechnologies, University of Messina, 98125 Messina, Italy

Received 15 November 2010; Accepted 19 February 2011

Academic Editor: Oscar Fernandez

Copyright © 2011 Rosalia D'Angelo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Bosnjak-Pasić, B. Vidrih, S. Miskov, and V. Demarin, “Treatment of multiple sclerosis,” Acta Clinica Croatica, vol. 48, no. 3, pp. 349–353, 2009. View at Google Scholar · View at Scopus
  2. A. Compston and A. Coles, “Multiple sclerosis,” Lancet, vol. 359, no. 9313, pp. 1221–1231, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. T. Hansen, A. Skytthe, E. Stenager, H. C. Petersen, H. Brønnum-Hansen, and K. O. Kyvik, “Concordance for multiple sclerosis in Danish twins: an update of a nationwide study,” Multiple Sclerosis, vol. 11, no. 5, pp. 504–510, 2005. View at Publisher · View at Google Scholar · View at Scopus
  4. C. J. Willer, D. A. Dyment, N. J. Risch et al., “Twin concordance and sibling recurrence rates in multiple sclerosis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 22, pp. 12877–12882, 2003. View at Publisher · View at Google Scholar · View at PubMed
  5. J. Yan and J. M. Greer, “NF-κB, a potential therapeutic target for the treatment of multiple sclerosis,” CNS and Neurological Disorders, vol. 7, no. 6, pp. 536–557, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Pugliatti, H. F. Harbo, T. Holmøy et al., “Environmental risk factors in multiple sclerosis,” Acta Neurologica Scandinavica, vol. 117, no. 188, pp. 34–40, 2008. View at Publisher · View at Google Scholar · View at PubMed
  7. S. V. Ramagopalan, G. C. DeLuca, A. Degenhardt, and G. C. Ebers, “The genetics of clinical outcome in multiple sclerosis,” Journal of Neuroimmunology, vol. 201-202, pp. 183–199, 2008. View at Publisher · View at Google Scholar · View at PubMed
  8. R. M. Ransohoff, “Mechanisms of inflammation in MS tissue: adhesion molecules and chemokines,” Journal of Neuroimmunology, vol. 98, no. 1, pp. 57–68, 1999. View at Publisher · View at Google Scholar
  9. F. Sellebjerg and T. L. Sørensen, “Chemokines and matrix metalloproteinase-9 in leukocyte recruitment to the central nervous system,” Brain Research Bulletin, vol. 61, no. 3, pp. 347–355, 2003. View at Publisher · View at Google Scholar
  10. J. Imitola, T. Chitnis, and S. J. Khoury, “Cytokines in multiple sclerosis: from bench to bedside,” Pharmacology and Therapeutics, vol. 106, no. 2, pp. 163–177, 2005. View at Publisher · View at Google Scholar · View at PubMed
  11. B. M. Segal, “CNS chemokines, cytokines, and dendritic cells in autoimmune demyelination,” Journal of the Neurological Sciences, vol. 228, no. 2, pp. 210–214, 2005. View at Publisher · View at Google Scholar · View at PubMed
  12. L. Cartier, O. Hartley, M. Dubois-Dauphin, and K. H. Krause, “Chemokine receptors in the central nervous system: role in brain inflammation and neurodegenerative diseases,” Brain Research Reviews, vol. 48, no. 1, pp. 16–42, 2005. View at Publisher · View at Google Scholar · View at PubMed
  13. T. Vyshkina, Y. Y. Shugart, G. Birnbaum, T. P. Leist, and B. Kalman, “Association of haplotypes in the β-chemokine locus with multiple sclerosis,” European Journal of Human Genetics, vol. 13, no. 2, pp. 240–247, 2005. View at Publisher · View at Google Scholar · View at PubMed
  14. M. Samson, F. Libert, B. J. Doranz et al., “Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene,” Nature, vol. 382, no. 6593, pp. 722–726, 1996. View at Publisher · View at Google Scholar · View at PubMed
  15. R. Liu, W. A. Paxton, S. Choe et al., “Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection,” Cell, vol. 86, no. 3, pp. 367–377, 1996. View at Publisher · View at Google Scholar
  16. H. Deng, R. Liu, W. Ellmeier et al., “Identification of a major co-receptor for primary isolates of HIV-1,” Nature, vol. 381, no. 6584, pp. 661–666, 1996. View at Publisher · View at Google Scholar · View at PubMed
  17. R. Bonecchi, G. Bianchi, P. P. Bordignon et al., “Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s,” Journal of Experimental Medicine, vol. 187, no. 1, pp. 129–134, 1998. View at Publisher · View at Google Scholar
  18. J. B. Rottman, K. P. Ganley, K. Williams, L. Wu, C. R. Mackay, and D. J. Ringler, “Cellular localization of the chemokine receptor CCR5: correlation to cellular targets of HIV-1 infection,” American Journal of Pathology, vol. 151, no. 5, pp. 1341–1351, 1997. View at Google Scholar
  19. L. F. Barcellos, A. M. Schito, J. B. Rimmler et al., “CC-chemokine receptor 5 polymorphism and age of onset in familial multiple sclerosis,” Immunogenetics, vol. 51, no. 4-5, pp. 281–288, 2000. View at Google Scholar
  20. R. Kantor, M. Bakhanashvili, and A. Achiron, “A mutated CCR5 gene may have favorable prognostic implications in MS,” Neurology, vol. 61, no. 2, pp. 238–240, 2003. View at Google Scholar
  21. F. Sellebjerg, H. O. Madsen, C. V. Jensen, J. Jensen, and P. Garred, “CCR5 Δ32, matrix metalloproteinase-9 and disease activity in multiple sclerosis,” Journal of Neuroimmunology, vol. 102, no. 1, pp. 98–106, 2000. View at Publisher · View at Google Scholar
  22. O. H. Kantarci, Y. Morales, P. A. Ziemer et al., “CCR5Δ32 polymorphism effects on CCR5 expression, patterns of immunopathology and disease course in multiple sclerosis,” Journal of Neuroimmunology, vol. 169, no. 1-2, pp. 137–143, 2005. View at Publisher · View at Google Scholar · View at PubMed
  23. S. Ristić, L. Lovrečić, N. Starčevié-Čizmarević et al., “No association of CCR5Δ32 gene mutation with multiple sclerosis in Croatian and Slovenian patients,” Multiple Sclerosis, vol. 12, no. 3, pp. 360–362, 2006. View at Publisher · View at Google Scholar
  24. J. A. Silversides, S. V. Heggarty, G. V. McDonnell, S. A. Hawkins, and C. A. Graham, “Influence of CCR5 δ32 polymorphism on multiple sclerosis susceptibility and disease course,” Multiple Sclerosis, vol. 10, no. 2, pp. 149–152, 2004. View at Publisher · View at Google Scholar
  25. D. R. Kaimen-Maciel, E. M. Vissoci Reiche, D. G. Brum Souza et al., “CCR5-Delta32 genetic polymorphism associated with benign clinical course and magnetic resonance imaging findings in Brazilian patients with multiple sclerosis,” International Journal of Molecular Medicine, vol. 20, no. 3, pp. 337–344, 2007. View at Google Scholar
  26. C. M. Poser, D. W. Paty, and L. Scheinberg, “New diagnostic criteria for multiple sclerosis: guidelines for research protocols,” Annals of Neurology, vol. 13, no. 3, pp. 227–231, 1983. View at Google Scholar
  27. J. Sambrook, E. F. Fritsch, and T. Maniatis, Molecular Cloning: Alboratory Manual, Cold Spring Harbour Laboratory, New York, NY, USA, 2nd edition, 1989.
  28. I. StatSoft, “Statistica per Windows,” StatSoft Italia srl, 1995.
  29. M. Shahbazi, H. Ebadi, D. Fathi et al., “CCR5-Delta32 allele is associated with the risk of developing multiple sclerosis in the Iranian population,” Cellular and Molecular Neurobiology, vol. 29, no. 8, pp. 1205–1209, 2009. View at Publisher · View at Google Scholar · View at PubMed
  30. F. Sellebjerg, T. B. Kristiansen, P. Wittenhagen et al., “Chemokine receptor CCR5 in interferon-treated multiple sclerosis,” Acta Neurologica Scandinavica, vol. 115, no. 6, pp. 413–418, 2007. View at Publisher · View at Google Scholar · View at PubMed
  31. D. Otaegui, J. Ruíz-Martínez, J. Olaskoaga, J. I. Emparanza, and A. L. De Munain, “Influence of CCR5-Δ32 genotype in Spanish population with multiple sclerosis,” Neurogenetics, vol. 8, no. 3, pp. 201–205, 2007. View at Publisher · View at Google Scholar · View at PubMed
  32. M. Luomala, T. Lehtimäki, H. Huhtala et al., “Promoter polymorphism of IL-10 and severity of multiple sclerosis,” Acta Neurologica Scandinavica, vol. 108, no. 6, pp. 396–400, 2003. View at Publisher · View at Google Scholar
  33. C. G. Haase, S. Schmidt, and P. M. Faustmann, “Frequencies of the G-protein β3 subunit C825T polymorphism and the δ 32 mutation of the chemokine receptor-5 in patients with multiple sclerosis,” Neuroscience Letters, vol. 330, no. 3, pp. 293–295, 2002. View at Publisher · View at Google Scholar
  34. C. Gerard and B. J. Rollins, “Chemokines and disease,” Nature Immunology, vol. 2, no. 2, pp. 108–115, 2001. View at Google Scholar
  35. M. J. Eikelenboom, J. Killestein, T. Izeboud et al., “Chemokine receptor expression on T cells is related to new lesion development in multiple sclerosis,” Journal of Neuroimmunology, vol. 133, no. 1-2, pp. 225–232, 2002. View at Publisher · View at Google Scholar
  36. B. R. Lane, D. M. Markovitz, N. L. Woodford, R. Rochford, R. M. Strieter, and M. J. Coffey, “TNF-α inhibits HIV-1 replication in peripheral blood monocytes and alveolar macrophages by inducing the production of RANTES and decreasing C-C chemokine receptor 5 (CCR5) expression,” Journal of Immunology, vol. 163, no. 7, pp. 3653–3661, 1999. View at Google Scholar
  37. J. Simpson, P. Rezaie, J. Newcombe, M. L. Cuzner, D. Male, and M. N. Woodroofe, “Expression of the β-chemokine receptors CCR2, CCR3 and CCR5 in multiple sclerosis central nervous system tissue,” Journal of Neuroimmunology, vol. 108, no. 1-2, pp. 192–200, 2000. View at Publisher · View at Google Scholar
  38. P. A. Calabresi, R. Martin, and S. Jacobson, “Chemokines in chronic progressive neurological diseases: HTLV-1 associated myelopathy and multiple sclerosis,” Journal of Neurovirology, vol. 5, no. 1, pp. 102–108, 1999. View at Google Scholar
  39. T. Strunk, S. Bubel, B. Mascher, P. Schlenke, H. Kirchner, and K. P. Wandinger, “Increased numbers of CCR5+ interferon-γ- and tumor necrosis factor-α- secreting T lymphocytes in multiple sclerosis patients,” Annals of Neurology, vol. 47, no. 2, pp. 269–273, 2000. View at Publisher · View at Google Scholar
  40. A. Sidoti, R. D'Angelo, C. Rinaldi et al., “Distribution of the mutated Δ32 allele of the CCR5 gene in a Sicilian population,” International Journal of Immunogenetics, vol. 32, no. 3, pp. 193–198, 2005. View at Publisher · View at Google Scholar · View at PubMed
  41. A. Sidoti, R. Robledo, A. Rinaldi, R. D'Angelo, C. Rinaldi, and A. Amato, “Further data on a 9.1-kb insertion-deletion polymorphism: survey of mediterranean populations,” Human Biology, vol. 78, no. 3, pp. 371–378, 2006. View at Google Scholar